Pancreatic cancer kills largely because it hides. There is no routine screening test, early symptoms are easy to miss, and the five-year survival rate is about 13%. A liquid biopsy described in Nature Medicine aims to move detection earlier.
The assay is called PANXEON. It reads three signals from one blood draw: circulating microRNAs, exosomal microRNAs and the protein CA19-9. An AI layer combines those readings into a single composite risk score. Across a study of nearly 1,800 people in the United States, Europe and Asia, it flagged stage 1 and stage 2 disease roughly 87% of the time, with a low rate of false positives.
The more striking number concerns disease that has not turned invasive. Among patients carrying high-risk pancreatic cysts, the test picked up high-grade dysplasia more than 64% of the time. That lesion is often described as stage 0 pancreatic cancer, and finding it could create a window to intervene.
City of Hope, which runs the Stephenson Global Pancreatic Cancer Research Institute, frames the test as a triage step rather than a replacement for imaging. Its job would be sorting high-risk patients – people with cysts, chronic pancreatitis or inherited risk – toward further evaluation.
Specificity is the open question. An outside oncologist called the sensitivity promising but said the assay needs sharper specificity before widespread use in high-risk groups. The stakes are visible in the survival curve: pancreatic cancer found while still localized runs about 44% five-year survival, against 3% once it has spread.
